Sanders’s bill would allow the Medicare prescription drug program to negotiate prices with drug companies, which is currently banned under a 2003 law. The measure would also allow the importation of drugs from Canada.
It requires drug companies to report information about factors that affect pricing, such as research and development costs. Pharmaceutical companies say they are producing groundbreaking new cures that are difficult and expensive to develop.